Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer

Inclusion Criteria: * Histologically or cytologically confirmed stage IV breast cancer * Patients without pathologic or cytologic confirmation of metastatic disease must have unequivocal evidence of metastasis by physical exam or radiologic study * Must meet 1 of the following criteria: * Received 1 or 2 prior conventional chemotherapy regimens for metastatic disease * Relapsed within 1 year after adjuvant chemotherapy and no prior chemotherapy for metastatic disease * At least 1 unidimensionally measurable lesion, meeting 1 of the following criteria: * At least 20 mm by conventional techniques * At least 10 mm by spiral CT scan * No CNS metastases by CT scan or MRI within the past 6 weeks * No prior or concurrent primary CNS tumor on physical exam * Disease progression after bone marrow or peripheral blood stem cell transplantation allowed * HER2-positive tumors allowed if previously treated with trastuzumab (Herceptin) * Hormone receptor status: * Not specified * Male or female * Performance status - ECOG 0-2 * Performance status - Karnofsky 60-100% * More than 3 months * Absolute neutrophil count at least 1,500/mm\^3 * Hemoglobin at least 9 g/dL * Platelet count at least 100,000/mm\^3 * No prior bleeding diathesis or coagulopathy * Bilirubin no greater than 1.5 times upper limit of normal (ULN) * AST/ALT no greater than 2.5 times ULN * INR no greater than 1.5 * Creatinine less than 2 mg/dL * Urine protein no greater than +1 by dipstick * Urine protein less than 500 mg by 24-hour urine collection * LVEF at least 50% * No prior stroke * No New York Heart Association class II-IV congestive heart failure * No serious cardiac arrhythmia requiring medication, including atrial fibrillation requiring systemic anticoagulation * No grade II or greater peripheral vascular disease within the past year * No clinically significant peripheral artery disease * No deep vein thrombosis or embolism within the past 5 years * No arterial thromboembolic event within the past 6 months, including any of the following: * Transient ischemic attack * Cerebrovascular accident * Unstable angina * Myocardial infarction * No other significant cardiovascular disease * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No evidence of seizures not controlled with standard medical therapy * No prior allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or other agents used in the study * Prior mild infusion reaction to trastuzumab allowed * No serious non-healing wound, ulcer, or bone fracture * No significant traumatic injury within the past 4 weeks * No other concurrent illness (such as active infection) that would require active treatment or preclude study * No psychiatric illness or social situation that would preclude study * See Disease Characteristics * No prior bevacizumab * No other prior experimental angiogenesis inhibitors * At least 2 weeks since prior trastuzumab and recovered * Concurrent epoetin alfa or filgrastim (G-CSF) allowed * See Disease Characteristics * At least 2 weeks since prior chemotherapy and recovered * No prior vinorelbine * No more than 2 prior conventional chemotherapy regimens for metastatic breast cancer * Prior hormonal therapy allowed * At least 1 week since prior radiotherapy and recovered * No concurrent radiotherapy * At least 4 weeks since prior major surgical procedure or open biopsy * At least 1 week since prior fine-needle aspiration except in the breast * No concurrent major surgical procedure * Recovered from the toxic effects of any prior therapy * At least 10 days since prior oral or parenteral anticoagulants (e.g., heparin or warfarin) except to maintain the patency of permanent, indwelling central venous catheter * At least 10 days since prior thrombolytic agents * No chronic aspirin therapy greater than 325 mg per day or non-steroidal anti-inflammatory medications that inhibit platelet function * No concurrent COX-2 inhibitors that inhibit platelet function * No other concurrent investigational or commercial agents or therapies for the malignancy * No concurrent antiretroviral therapy for HIV-positive patients * No concurrent ketoconazole, zidovudine, or macrolide antibiotics * No concurrent oral or parenteral anticoagulants except to maintain patency of permanent, indwelling central venous catheter * No concurrent thrombolytic agent * Concurrent bisphosphonates allowed * Concurrent celecoxib or rofecoxib allowed